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Abstract. In contrast to morphological imaging [such as 
magnetic resonance imaging (MRI) or computed tomog- 
raphy], functional imaging may be of advantage in the 
detection of brain abnormalities in cases of neuropsyehi- 
atric systemic lupus erythematosus (SLE). Therefore, we 
studied 13 patients (aged 40_+14 years, 11 female, 2 
male) with neuropsychiatric SLE who met four of the 
American Rheumatism Association criteria for the clas- 
sification of SLE. Ten clinically and neurologically heal- 
thy volunteers erved as controls (aged 40+12 years, 5 
female, 5 male). Both groups were investigated using 
fluorine-18-1abelled fluorodeoxyglucose brain positron 
emission tomography (PET) and cranial MRI. The nor- 
mal controls and 11 of the 13 patients howed normal 
MRI scans. However, PET scan was abnormal in all 13 
SLE patients. Significant group-to-group differences in 
the glucose metabolic index (GMI=region of interest up- 
take/global uptake at the level of the basal ganglia and 
thalamus) were found in the parieto-occipital region on 
both sides: the GMI of the parieto-oceipital region on 
the right side was 0.922+0.045 in patients and 
1.066+0.081 in controls (P<0.0001, Mann Whitney U 
test), while on the left side it was 0.892+0.060 in pa- 
tients and 1.034+0.051 in controls (P=0.0002). Parieto- 
occipital hypometabolism is a conspicuous finding in 
mainly MRl-negative neuropsychiatric SLE. As the pari- 
eto-occipital region is located at the boundary of blood 
supply of all three major arteries, it could be the most 
vulnerable zone of the cerebrum and may be affected at 
an early stage of the cerebrovascular disease. 
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Introduction 
Studies with positron emission tomography (PET) and 
single-photon emission tomography (SPET) have shown 
that in certain brain disorders functional imaging is more 
sensitive than morphological imaging such as magnetic 
resonance imaging (MRI) and X-ray computed tomogra- 
phy. This applies to traumatic brain injury [1-8], whip- 
lash injury [9, 10], migraine [11], or Alzheimer's disease 
[12, 13], and also neuropsychiatric systemic lupus ery- 
thematosus (SLE) [14-16]. Neuropsychiatric SLE has in 
most cases been studied in late stages of the disease; lit- 
tle is known of early neuropsychiatric SLE. There are 
conflicting reports regarding the regions involved in neu- 
ropsychiatric SLE: using azetazolamide-enhanced SPET
in an SLE patient with preclinical central nervous 
system (CNS) involvement, GdJnwald et al. [14] showed 
a marked reduction in the cortical perfusion reserve, par- 
ticularly in both frontal obes, whereas Kovacs et al. [17] 
showed various other abnormal regions such as the oc- 
cipital cortex or the basal ganglia in cases of active neu- 
ropsychiatric SLE. Szer et al. [18] reported on a girl 
with a concurrent ischaemic event involving both pari- 
etal lobes. Therefore, we wondered whether there is a 
typical pattern of metabolism in neuropsychiatric SLE, 
reflecting the vulnerability of the different zones in the 
cerebrum. 
Materials and methods 
Each study participant signed an informed consent form, explain- 
ing the investigative nature of the study, its risks, and its merits. 
Study population. Ten normal controls (mean age 40___12 years, 5 
female, 5 male) and 13 patients (mean age 40_+14 years, 11 re- 
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male, 2 male) were studied. All patients met four of the American 
Rheumatism Association criteria for the classification of SLE 
[19]. All study participants were interviewed with regard to head- 
ache, vertigo, visual symptoms (blurred vision, scintillating scoto- 
ma, oscillopsia), impaired memory and/or concentration, depres- 
sion, sleep disturbances, anxiety and instability [20]. 
None of the study participants exhibited anamnestic hints of 
neurovascular o  neurodegenerative diseases. Secondary causes 
such as infection, uraemia, hypertension, drugs and metabolic ab- 
normalities were excluded. Eleven of the 13 neuropsychiatric SLE 
patients received corticosteroid treatment and three received im- 
munosuppression with cyclophosphamide or azathioprine. As re- 
gards the control group, only participants with normal clinical and 
neurological findings were included in the study. For the patient 
group, only those patients were included who showed clinical and 
neurological findings indicating CNS involvement by the disease. 
Neuropsychiatric manifestation due to SLE was defined as an ab- 
normality of neurological function identified by current history 
and physical examination and noted as a change from a prior state, 
if this abnormality could not be attributed to any cause other than 
the disease process itself. The CNS manifestations were classified 
into "major" (seizures, focal motor or sensory deficits, generalized 
disturbances, psychosis, organic brain syndrome) and "minor" 
signs (paraesthesia or clumsiness without objective findings, 
headache, cognitive disorders) according to the classification of 
How et al. [21]. Nine patients with "initial" CNS SLE had shown 
neuropsychiatric signs for no longer than 1 year, whereas four pa- 
tients with "manifest" CNS disease had been symptomatic for 
more than 1 year. All patients diagnosed as having manifest CNS 
SLE (n=4) had one or more major signs, and two of them showed 
pathological findings on MRI. Patients in the initial CNS SLE 
group had one major sign (n=5) or one to three minor signs 
(n =4). 
MRI of the brain was also undertaken i all patients and con- 
trois. 
The following neuropsychiatric symptoms were observed in 
the SLE patients: 
- Impairment of memory and of intelligent function: n=6 patients 
- Psychosis: n=4 
- Seizure: n=l 
- Focal motor deficits: n=2 
- Persistent headache: n=4 
- Paraesthesia: n=2 
- Vertigo: n=3 
- Impairment of orientation and perception: =l 
- Visual symptoms: n=4 
- Recurrent apoplexy: n= 1 
The following concomitant clinical and serological parameters 
were observed in the SLE patients: 
- Positive antinuclear ntibodies: n = 13 patients 
- Positive anti-ds DNA: n=7 
- Positive antibodies against extractable nuclear antigen: n= 10 
- Phospholipid antibodies: n=6 
- Cutaneous lesions: n=7 
Lupus nephritis: n=8 
- Arthralgia: n=6 
- Myalgia: n=4 
- Sicca complex: n=4 
- Cytopenia: n=4 
Radiopharmaceuticals. All participants were injected with 
370 MBq fluorine-I 8 fluorodeoxyglucose (FDG) into a peripheral 
vein. FDG was synthesized and prepared as reported previously 
[22]. 
PET study protocol. Before the start of the PET procedure, each 
study participant had to fast for at least 12 h before the study and 
to empty the bladder. Then, during the 10-rain waiting period pri- 
or to injection, patients and controls were placed on a bed in the 
preparation area in a quiet room with dim lights, remaining 
awake, but with closed eyes. After injection, patients and controls 
remained on the bed for another 30 min. The head of each subject 
was then positioned parallel to the orbitomeatal line with the aid 
of a laser beam, after which it was placed in a moulded thermo- 
plastic head support to minimize head movements during the 
scanning procedure. All subjects were studied at rest. The acquisi- 
tion started about 35 min p.i. PET imaging was performed on a 
Siemens CTI ECAT EXACT tomograph. This device records 31 
planes simultaneously, which encompass a 10.8-cm field of view. 
The spatial resolution is 6.0 mm full-width at half-maximum. 
Photon attenuation was automatically calculated using Siemens- 
CTI standard software [23]. A total of six frames, each of 5 rain 
duration, were acquired. Images were reconstructed using filtered 
back-projection (Shepp-Logan filter, cut-off 0.3 cycles/pixel). For 
data analysis, summed images were used (summing the dynami- 
cally acquired frames 1-6 into one image). 
Data analysis. Standardized cortical and subcortical elliptical re- 
gions of interest (ROIs) were assigned to three adjacent transaxial 







6. Parieto-occipital (P-O) 
7. Thalamus 
8. Putamen 
9. Caudate nucleus 
10. Cerebellar (mean of lateral and dorsal cerebellum) 
11. Brain stem 
12. Global at the level of the thalamus and basal ganglia 
The shape and size of ROIs were the same in all patients and 
controls, since the ROI templates were copied onto the corre- 
sponding planes of each study. The shape and size of global ROIs 
were fitted to actual head form by manipulation. The position of 
all ROIs was adjusted to the corresponding anatomical localiza- 
tion. In each ROI the average uptake per pixel per time was deter- 
mined. 
ROI analysis was performed using a SUN sparc station and 
SUNVIEW software. To allow inter-individual comparisons, re- 
gional cerebral metabolism was normalized by global glucose me- 
tabolism (glucose metabolic index, GMI; GMI=ROI uptake/global 
uptake) determined from the global brain ROI at the level of the 
thalamus and basal ganglia. 
Statistical analysis. All data are expressed as mean _+1 SD. Group- 
to-group differences were tested using the Mann Whitney U test 
(M.W.) and the software StatView 4.10. 
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Results 
MRI of the brain showed no pathological findings in any 
of the controls or in 11 of the 13 patients. The two pa- 
tients with pathological MRI findings had had organic 































Fig. 1. Scattergrams of" GMI values of P-O on the right (a) and left 
(b) sides, in the control group (con, n=10) and the patient group 
(pat, n= 13) 
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trast, the patient group revealed a significant hypometab- 
olism in the P-O regions [on the right (R) and left (L) 
side] as compared to the control group (Fig. 1): 
- GMI P-O R: controls 1.066+0.081, patients 
0.922_+0.045; P<0.0001 
- GMI P-O L: controls 1.034___0.051, patients 
0.892___0.060; P=0.0002 
Group-to-group differences in regions other than the 
P-O were not statistically significant. However, careful 
evaluation of the individual metabolic pattern did addi- 
tionally reveal, in six of the 13 patients (46%), GMI val- 
ues which were more than one or two standard devia- 
tions below normal control values in regions other than 
the P-O. In one patient (no. 5), P-O hypometabolism was 
combined with a patchy uptake pattern over the whole 
brain, while in another (no. 1) it was combined with a 
relative hypermetabolism in the basal ganglia and thala- 
mi (Table 1 ). 
Furthermore, when the SLE patient group was divid- 
ed into patients who showed CNS involvement for the 
first time at admission (group 1, n=9) and patients with 
organic neuropsychiatric symptoms for more than 1 year 
(group 2, n=4), no significant difference was found be- 
tween groups 1 and 2 with regard to glucose utilization 
in any of the analysed brain regions. 
Discussion 
Our study indicates that ueuropsychiatric SLE - irre- 
spective of the stage of CNS involvement (i.e. initial or 
non-initial) - has a typical pattern of hypometabolism in 
the P-O region, although non-P-O regions may also be 
affected. Since the P-O region is located at the boundary 
of supply of all three major arteries, it is thought o be 
the most vulnerable zone of the cerebrum [24]. There- 
Table 1. Brain PET findings in patients 
Pat. P-o,R P-o,L ER EL ER F,L O-ER O-F,L CN,B PUT, B TH,B P-P 
1 - -  0 O 0 0 0 0 ++ ++ ++ No 
2 . . . . . . . . . . . . .  0 0 0 0 No 
3 -- 0 0 ~ 0 0 0 0 0 O No 
4 . . . .  0 0 0 0 0 0 0 0 0 No 
5 . . . .  0 0 0 0 0 O 0 0 O Yes 
6 -- 0 0 0 0 O 0 O 0 0 No 
7 - 0 0 0 0 0 0 0 No 
8 0 0 O 0 0 0 0 0 0 0 No 
9 . . . . . .  O 0 0 0 0 0 0 0 No 
10 . . . . . .  0 0 0 0 0 0 0 0 No 
11 -- 0 0 0 0 0 0 0 0 No 
12 . . . .  O 0 0 0 + 0 0 No 
13 -- O 0 0 0 0 O 0 O O No 
P-O, Parieto-occipital; P, parietal; F, frontal; O-F, occipito-frontal; CN, caudate nucleus; PUT, putamen; TH, thalamus; P-P, patchy uptake 
pattern; R, right brain side; L, left brain side; B, both sides. -, GMI>I SD below normal controls; - -, >2 SD; +, GMI>I SD above normal 
controls; ++, >2 SD; Q, GMI within normal imits. 
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fore, we think that this region is frequently affected at an 
early stage of SLE with suspected CNS involvement. 
MRI findings are inconspicuous in early neuropsychiat- 
ric SLE, in contrast o the well-known MRI findings in 
manifest and chronic CNS SLE [25-27]; against this 
background the information provided by our PET data 
might have important diagnostic and therapeutic impli- 
cations at an early stage of the disease. However, the 
question of whether vasculitis or infarctions and haem- 
orrhages in this P-O zone are the consequence or a cause 
of the SLE process remains open. 
Abnormalities in the P-O region are not pathogno- 
monic for neuropsychiatric SLE: they can also be found, 
for example, in the late whiplash syndrome [9, 10, 28], 
in dementia of the Alzheimer type [12], in the elderly 
[13], in sleep apnea syndrome [13] and following cere- 
bral hypoxia [13]. However, after careful clinical and se- 
rological classification of our neuropsychiatric SLE pa- 
tients, these differential diagnoses could be excluded. 
In studies on the pathology of cerebral lupus, vascu- 
lopathy, infarctions and haemorrhages are often ob- 
served, whereas vasculitis is rare [29]. Furthermore, the 
concept of hypercoagulability n SLE patients has divert- 
ed the direction of therapy from immunosuppression 
[30] (as in the majority of our patients) towards antico- 
agulation [31]. Randomized trials have commenced in 
order to determine the optimal mode of therapy for SLE 
patients under strict inclusion criteria, based on well-de- 
fined patient categories. Functional imaging like PET, or 
SPET, could be a powerful tool for such an enterprise. 
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